Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy

NCT03480971 is registered in ClinicalTrials.gov with Matrix Biomed, Inc. as lead sponsor.

NCT NCT03480971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03480971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy
Lead sponsor
Matrix Biomed, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
May 13, 2019
Completion date
December 31, 2025
Enrollment
120 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

mucositis, nephrotoxicity, ototoxicity